Efficacy of synbiotic supplementation in improving rheumatoid arthritis.
Disease activity
Rheumatoid arthritis
Synbiotics
Journal
Research in pharmaceutical sciences
ISSN: 1735-5362
Titre abrégé: Res Pharm Sci
Pays: Iran
ID NLM: 101516968
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
01
11
2019
revised:
19
04
2020
accepted:
23
04
2020
entrez:
22
10
2020
pubmed:
23
10
2020
medline:
23
10
2020
Statut:
epublish
Résumé
Today, improving rheumatoid arthritis (RA) as a chronic inflammatory disease is attributed to the proper status of the gut microbiota. Although some supplements containing beneficial live microorganisms (probiotics) can reduce inflammation by altering the bacterial composition of the gut, there is limited information on the effect of synbiotic (probiotics mixed with prebiotics) supplements on RA. Therefore, this study aimed to evaluate the anti-inflammatory effects of a synbiotic supplement as an adjuvant therapy in rheumatic patients. Moreover, for the first time, it was attempted to investigate whether addition of a synbiotic (1000 mg/day) to the combination of methotrexate and prednisolone increases the effectiveness of these antirheumatic drugs. Eligible patients (186 subjects) were randomly divided into two groups. Both groups received their standard routine antirheumatic drugs, methotrexate and prednisolone. Moreover, the first group received a daily oral synbiotic supplement (1000 mg) for 3 months while the second group received a placebo. Various parameters indicating RA status were evaluated at baseline (time 0) and 3 months after the treatment. The results showed the changes in the level of RA indicators, including tender joint count with a range of 0 to 28 joints, swollen joint count with a range of 0 to 28 joints, visual analog scale, erythrocyte sedimentation rate, CRP, and disease activity score based on 28 joints, after 3 months. Overall, no significant differences in the measured parameters were observed between synbiotic and placebo groups probably due to the short duration of the treatment period, and it is suggested to extend the treatment period to six months.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Today, improving rheumatoid arthritis (RA) as a chronic inflammatory disease is attributed to the proper status of the gut microbiota. Although some supplements containing beneficial live microorganisms (probiotics) can reduce inflammation by altering the bacterial composition of the gut, there is limited information on the effect of synbiotic (probiotics mixed with prebiotics) supplements on RA. Therefore, this study aimed to evaluate the anti-inflammatory effects of a synbiotic supplement as an adjuvant therapy in rheumatic patients. Moreover, for the first time, it was attempted to investigate whether addition of a synbiotic (1000 mg/day) to the combination of methotrexate and prednisolone increases the effectiveness of these antirheumatic drugs.
EXPERIMENTAL APPROACH
METHODS
Eligible patients (186 subjects) were randomly divided into two groups. Both groups received their standard routine antirheumatic drugs, methotrexate and prednisolone. Moreover, the first group received a daily oral synbiotic supplement (1000 mg) for 3 months while the second group received a placebo. Various parameters indicating RA status were evaluated at baseline (time 0) and 3 months after the treatment.
FINDINGS / RESULTS
UNASSIGNED
The results showed the changes in the level of RA indicators, including tender joint count with a range of 0 to 28 joints, swollen joint count with a range of 0 to 28 joints, visual analog scale, erythrocyte sedimentation rate, CRP, and disease activity score based on 28 joints, after 3 months.
CONCLUSION AND IMPLICATIONS
CONCLUSIONS
Overall, no significant differences in the measured parameters were observed between synbiotic and placebo groups probably due to the short duration of the treatment period, and it is suggested to extend the treatment period to six months.
Identifiants
pubmed: 33088326
doi: 10.4103/1735-5362.288432
pii: RPS-15-263
pmc: PMC7540809
doi:
Types de publication
Journal Article
Langues
eng
Pagination
263-272Informations de copyright
Copyright: © 2020 Research in Pharmaceutical Sciences.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Front Immunol. 2017 Jun 30;8:754
pubmed: 28713378
Arthritis Rheum. 2002 Oct;46(10):2553-63
pubmed: 12384910
Ann Rheum Dis. 2012 Jul;71(7):1190-6
pubmed: 22454398
Nat Rev Drug Discov. 2003 Jun;2(6):473-88
pubmed: 12776222
N Engl J Med. 2004 Jun 17;350(25):2591-602
pubmed: 15201416
Pharmacol Rep. 2006 Jul-Aug;58(4):473-92
pubmed: 16963793
Br J Nutr. 2017 Apr;117(8):1095-1102
pubmed: 28490394
Immunity. 2010 Jun 25;32(6):815-27
pubmed: 20620945
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14
pubmed: 24912386
Int J Rheum Dis. 2016 Sep;19(9):869-79
pubmed: 27135916
Mol Immunol. 2008 May;45(9):2690-9
pubmed: 18243320
Arthritis Res. 2002;4 Suppl 3:S265-72
pubmed: 12110146
Am J Clin Nutr. 2001 Feb;73(2 Suppl):361S-364S
pubmed: 11157342
PLoS One. 2016 May 26;11(5):e0154090
pubmed: 27228093
BMC Complement Altern Med. 2010 Jan 12;10:1
pubmed: 20067641
Foods. 2019 Mar 09;8(3):
pubmed: 30857316
Biochem Biophys Res Commun. 2013 May 17;434(4):740-5
pubmed: 23583379
WMJ. ;115(6):317-21
pubmed: 29094869
BMJ. 2006 Jan 21;332(7534):152-5
pubmed: 16424492
J Immunol Res. 2017;2017:4835189
pubmed: 28948174
Am J Health Syst Pharm. 2006 Dec 15;63(24):2451-65
pubmed: 17158693
Gastroenterol Res Pract. 2012;2012:872716
pubmed: 23049548
Health Promot Perspect. 2017 Mar 05;7(2):95-101
pubmed: 28326290
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Nutrients. 2017 Sep 15;9(9):
pubmed: 28914794
Rheumatology (Oxford). 2005 Nov;44(11):1414-21
pubmed: 16030080
Scand J Rheumatol. 2003;32(4):211-5
pubmed: 14626627
Res Pharm Sci. 2019 Dec 11;14(6):471-487
pubmed: 32038727
Trans Am Clin Climatol Assoc. 2013;124:16-25
pubmed: 23874006
J Food Sci Technol. 2015 Dec;52(12):7577-87
pubmed: 26604335
Ann Intern Med. 2012 Mar 6;156(5):329-39
pubmed: 22393128
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
Immunity. 2013 Aug 22;39(2):400-12
pubmed: 23973225
Inflammopharmacology. 2016 Oct;24(5):189-196
pubmed: 27581587
Lakartidningen. 2010 Mar 31-Apr 13;107(13-14):917
pubmed: 20432867
Arthritis Rheum. 2005 Sep;52(9):2625-36
pubmed: 16142705
Int J Rheum Dis. 2014 Jun;17(5):519-27
pubmed: 24673738
Am J Clin Nutr. 2001 Feb;73(2 Suppl):444S-450S
pubmed: 11157355
Clin Rheumatol. 2017 Dec;36(12):2697-2707
pubmed: 28914373
J Allergy Clin Immunol. 2005 Jun;115(6):1254-9
pubmed: 15940143
Clin Immunol. 2004 Dec;113(3):224-30
pubmed: 15507385
Microb Ecol Health Dis. 2015 Feb 02;26:26191
pubmed: 25651997
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595